Regulatory Approval Challenges: Sanuwave's ability to commercialize its medical devices, such as the dermaPACE System, is dependent on obtaining and maintaining stringent regulatory approvals from bodies like the FDA. Delays, failures, or unforeseen requirements in these processes could significantly impede product launch and market access.

Limited Market Adoption: Despite regulatory clearances, Sanuwave faces the challenge of gaining widespread acceptance and adoption of its proprietary shockwave therapy devices by healthcare providers, hospitals, and patients. Market penetration depends on perceived clinical benefits, ease of use, cost-effectiveness, and overcoming physician skepticism or inertia.

Financial Liquidity and Capital Needs: As a development-stage medical technology company, Sanuwave has historically operated at a loss and may require substantial additional capital to fund ongoing operations, research and development, and commercialization efforts. Failure to secure adequate funding could jeopardize its ability to continue as a going concern.